NCT06004388View on ClinicalTrials.gov

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

June 5, 2024

Conditions
MigraineEpisodic MigraineHeadacheHeadache, Migraine
Interventions
DEVICE

Click Digital Therapeutic

Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy

Trial Locations (1)

10013

Click Therapeutics, New York

Sponsors
All Listed Sponsors
lead

Click Therapeutics, Inc.

INDUSTRY